Puneeth Iyengar on the Benefits of Hypofractionated Radiation Therapy in Lung Cancer

Video

Dr. Puneeth Iyengar discusses the use of a hypofractioned course of radiation therapy for patients with stage 3 NSCLC instead of a combination of chemotherapy and radiation.

Puneeth Iyengar, MD, PhD, assistant professor of Radiation Oncology at UT Southwestern Medical Center, discusses the use of a hypofractionated course of radiation therapy for patients with stage 3 NSCLC.

The current standard therapy for stage 3 NSCLC is a combination of chemotherapy and radiation. Some patients are unable to tolerate chemotherapy for a variety of reasons and receive 6 weeks of radiation therapy instead. Iyengar's study compared that conventional schedule with a hypofractionated course, for just 3 weeks.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
Graphic reading "FDA Approved" resembling a stamp of approval

FDA Approves Larotrectinib for NTRK Fusion-Positive Solid Tumors

Bridget Hoyt
April 10th 2025
Article

The FDA approved larotrectinib for use in adult and pediatric patients with NTRK fusion-positive solid tumors with few other options.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Photo of a person's hand being examined by a person in medical clothes

COCOON Trial Regimen May Decrease Dermatologic AEs in EGFR+ NSCLC

Spencer Feldman
April 2nd 2025
Article

Per phase 2 trial data, enhanced dermatologic management showed a reduction in dermatologic AEs in patients with advanced EGFR-mutated NSCLC.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Anatomical rendering of a person's lungs

Pembrolizumab Combo May Benefit Elderly Metastatic NSCLC Cohort

Russ Conroy
March 15th 2025
Article

A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.

Image of a calendar with a thumb tack stuck on a day reading "20," and a stethoscope lying on the calendar, with an image of a clock overlaying

Opinion: Oncology Nurses Can Ease the Burden of Time Toxicity in Cancer Care

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
February 26th 2025
Article

Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.